Published in Cancer Chemother Pharmacol on January 01, 1990
Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer (2010) 0.97
The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics. J Neurooncol (2009) 0.80
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. Br J Cancer (2003) 0.79
Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. Br J Cancer (1994) 0.78
Programmed cell death in animal development. Cell (1997) 8.95
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol (2004) 3.97
Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol (2005) 3.34
Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol (2008) 3.07
[Primary cutaneous leiomyosarcoma: 32 cases]. Ann Dermatol Venereol (1999) 2.83
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood (1968) 2.71
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol (2002) 2.61
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol (1999) 2.34
High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A (1998) 2.30
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol (2007) 2.18
Role of Ced-3/ICE-family proteases in staurosporine-induced programmed cell death. J Cell Biol (1996) 2.17
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol (1996) 2.17
[Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases]. Presse Med (1967) 2.10
Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol (2009) 2.06
Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. J Neurosci (2000) 2.04
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer (1998) 1.98
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol (2009) 1.96
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer (2004) 1.93
Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer (2003) 1.90
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet (1998) 1.88
Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol (2004) 1.81
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial) Ann Oncol (2000) 1.80
A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics (1996) 1.75
The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol (1998) 1.70
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Added value of molecular targeted agents in oncology. Ann Oncol (2011) 1.65
HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol (1993) 1.60
Value of CA 15:3 in the follow-up of breast cancer patients. Br J Cancer (1987) 1.58
Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet (1969) 1.56
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol (2005) 1.54
P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol (2000) 1.53
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer (1993) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Modeling the spread of polio in an IPV-vaccinated population: lessons learned from the 2013 silent outbreak in southern Israel. BMC Med (2016) 1.46
Complete remission seven years after treatment for metastatic malignant melanoma. Cancer (1996) 1.45
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
Ofuji papuloerythroderma. Report of a case with T cell skin lymphoma and discussion of the nature of this disease. J Am Acad Dermatol (1989) 1.42
[Ki67 in young patients with breast cancer]. Gynecol Obstet Fertil (2013) 1.41
Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol (2013) 1.41
Unfading acral microlivedo. A discrete marker of thrombotic skin disease associated with antiphospholipid antibody syndrome. J Am Acad Dermatol (1991) 1.39
David Khayat: co-founder of The Charter of Paris Against Cancer (interview by Ezzie Hutchinson). Lancet Oncol (2001) 1.39
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol (2006) 1.37
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol (2005) 1.33
Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest (1993) 1.32
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol (1996) 1.31
Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol (1991) 1.31
Immunoscintigraphy of colon carcinoma. J Nucl Med (1984) 1.31
Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer (2000) 1.29
Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol (1996) 1.28
[Cardiac complications observed during treatment with rubidomycin]. Pathol Biol (1967) 1.27
EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer (2003) 1.25
Constitutive caspase-like machinery executes programmed cell death in plant cells. Cell Death Differ (2002) 1.25
Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol (1996) 1.25
Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer (2003) 1.24
Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology (1994) 1.24
Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol (2008) 1.23
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer (2002) 1.22
Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet (1986) 1.22
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol (1994) 1.21
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis? Aliment Pharmacol Ther (1998) 1.21
p53 mutations in skin and internal tumors of xeroderma pigmentosum patients belonging to the complementation group C. Cancer Res (1998) 1.20
Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res (1988) 1.20
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer (2003) 1.20
Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood (1973) 1.19
Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol (2005) 1.18
Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer (1990) 1.17
Goserelin depot in the treatment of premenopausal advanced breast cancer. Eur J Cancer (1992) 1.17
Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level. Br J Cancer (1988) 1.17
The importance of timing differentiation during limb muscle development. Curr Biol (1998) 1.17
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer (2011) 1.14